



## **Aurobindo Pharma declares Q2 2007-08 results Q2 TOTAL INCOME UP BY 38.9%, NET PROFIT UP BY 84.7% CONSOLIDATED Q2 NET PROFIT: Rs 62.05 crs**

Aurobindo Pharma is pleased to report robust growth in its Q2 financials. Sales grew to Rs. 640.81 crs (480.0), EBITDA Rs.145.38 crs (82.56), Net Profit Rs.100.92 crs (54.64).

API sales increased to Rs.426.17 crs (348.30) and Formulation Sales increased to Rs.214.64 crs (131.70).

Domestic sales increased to Rs.235.47 crs (199.80) and Exports sales increased to Rs 405.34 crs (280.20).

For the half year ended 30th September 2007, the Total Income, EBITDA and Net Profit stand at Rs.1,162 crs (883.86), Rs 232.25 crs (150.85) and Rs 159.46 crs (90.85) respectively.

### **Q2 Consolidated:**

During the Quarter ended 30th September 2007, the company has achieved Consolidated Total Income, EBITDA and PAT of Rs 655.38 crs, Rs 120.38 crs & Rs 62.06 crs respectively.

In continuation of company's efforts to penetrate into the European and South African markets, the company has set up Wholly Owned Subsidiary in Europe to focus on formulation business with IPR protection. The said subsidiary is engaged in identification of the products, development of Registration Dossier for said market by sub-contracting to Aurobindo India and third parties and commercialisation thereon. Accordingly, during Q2 the development of all such registration dossier has been undertaken by the said subsidiary to the extent of Rs.16.98 crs from Aurobindo India.

During the quarter, the company has received 10 ANDA approvals for USA market. The majority of the shipments for the newly approved products were made in September 2007 to our Wholly Owned Subsidiary Aurobindo USA, whereas their sales will get reflected in Q3.

In view of the above, the consolidated profit in Q2 is lower than stand alone profit.

### **AUROBINDO PHARMA LTD**

Aurobindo Pharma Limited ([www.aurobindo.com](http://www.aurobindo.com)), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company has received approvals for several facilities from leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics. The Company is marketing these products globally, in over 100 countries.